High LYVE-1 positive lymphatic vessel numbers are associated with axillary lymph node metastases and poor outcome in breast cancer. by Bono, P, Wasenius, V, Lundin, J, Jackson, D, Joensuu, H

High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. by Bono, P, Wasenius, V, Heikkilä, P, Lundin, J, Jackson, D, Joensuu, H

Analysis of four-wave mixing of high-power lasers for the detection of elastic photon-photon scattering by Lundin, J, Marklund, M, Lundström, E, Brodin, G, Collier, J, Bingham, R, Mendonça, J, Norreys, P

Using high-power lasers for detection of elastic photon-photon scattering by Lundström, E, Brodin, G, Lundin, J, Marklund, M, Bingham, R, Collier, J, Mendonça, J, Norreys, P

Deep learning based tissue analysis predicts outcome in colorectal cancer by Bychkov, D, Linder, N, Turkki, R, Nordling, S, Kovanen, P, Verrill, CL, Walliander, M, Lundin, M, Haglund, C, Lundin, J

Integrating digital and in-person therapy for PTSD: feasibility and acceptability of blended trauma-focused cognitive therapy in routine care by Lundin, J, Jansson-Fröjmark, M, Gustafsson-Björverud, L, Grey, N, Santoft, F, Ehlers, A, Carlbring, P, Lundgren, T, Bragesjö, M, Salomonsson, S

Deep learning for detecting tumour infiltrating lymphocytes in testicular germ cell tumors by Linder, N, Taylor, J, Colling, R, Pell, R, Alveyn, E, Joseph, J, Protheroe, A, Lundin, M, Lundin, J, Verrill, C

Breast cancer outcome prediction with tumour tissue images and machine learning by Turkki, R, Byckhov, D, Lundin, M, Isola, J, Nordling, S, Kovanen, PE, Verrill, C, von Smitten, K, Joensuu, H, Lundin, J, Linder, N

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). by Lundin, J, Kimby, E, Björkholm, M, Broliden, P, Celsing, F, Hjalmar, V, Möllgård, L, Rebello, P, Hale, G, Waldmann, H, Mellstedt, H, Osterborg, A

Molecular and clinical delineation of the 17q22 microdeletion phenotype by Laurell, T, Lundin, J, Nordenskjöld, A, Anderlid, B, Grigelioniene, G, Nordgren, A, Gorski, J, Knight, S, Krepischi, A, Price, S, Rosenberg, C, Vianna-Morgante, A, Turnpenny, P

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). by Lundin, J, Kimby, E, Bjorkholm, M, Celsing, F, Hale, G, Hjalmar, V, Merup, M, Petrescu, A, Tullgren, O, Waldmann, H, Mellstedt, H, Osterborg, A

Molecular and clinical delineation of the 17q22 microdeletion phenotype. by Laurell, T, Lundin, J, Anderlid, B, Gorski, J, Grigelioniene, G, Knight, S, Krepischi, A, Nordenskjöld, A, Price, S, Rosenberg, C, Turnpenny, P, Vianna-Morgante, A, Nordgren, A

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. by Hale, G, Rebello, P, Brettman, L, Fegan, C, Kennedy, B, Kimby, E, Leach, M, Lundin, J, Mellstedt, H, Moreton, P, Rawstron, A, Waldmann, H, Osterborg, A, Hillmen, P